https://www.biopharmadive.com/news/moderna-covid-vaccine-forecast-commercial-insurance/643413/
Moderna shares sink amid COVID forecasts, trial news | BioPharma Dive
The biotech expects to earn at least $5 billion from sales of its COVID vaccine this year, which would be about one-third of what it made in 2022.
moderna sharestrial newsbiopharma divesinkamid
https://www.biopharmadive.com/news/moderna-second-quarter-2024-sales-guidance-covid-rsv/723016/
Moderna shares fall amid lower sales outlook for RSV, COVID shots | BioPharma Dive
The biotech cited competitive pressure and “very low” expected sales in Europe for its latest guidance cut, which sent shares down by nearly 20%.
moderna shares